2466 completed, 884 terminated, 732 recruiting, 477 unknown. 5383 Phase 1, 1933 Phase 2.
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-11-02 |
| Lentiviral FIX Gene Therapy YUVA-GT-F901 - Hemophilia B | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-11-02 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Lentiviral FVIII Gene Therapy YUVA-GT-F801 - Hemophilia A | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-10-30 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Phase 1 | Not yet recruiting | Columbia University | 27 | 2027-03-01 | 2026-11-06 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-10-28 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
Showing 20 of 5383. Sign in to see all of them.
Leukemia, Myeloid, Acute (1480) · Multiple Myeloma (1193) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (838) · Leukemia, Lymphocytic, Chronic, B-Cell (794) · Leukemia (777) · Myelodysplastic Syndromes (703) · Lymphoma, Non-Hodgkin (542) · Lymphoma (494) · Recurrence (488) · Hematologic Neoplasms (411) · Lymphoma, Mantle-Cell (386) · Lymphoma, Follicular (380) · Lymphoma, Large B-Cell, Diffuse (374) · Lymphoma, B-Cell, Marginal Zone (323) · Burkitt Lymphoma (314)
Hemic and Lymphatic Diseases (5382) · Neoplasms (4121) · Neoplasms by Histologic Type (4060) · Immune System Diseases (2967) · Immunoproliferative Disorders (2762) · Lymphoproliferative Disorders (2740) · Leukemia (2252) · Lymphatic Diseases (1869) · Pathological Conditions, Signs and Symptoms (1854) · Pathologic Processes (1828) · Leukemia, Myeloid (1690) · Disease Attributes (1673) · Hemorrhagic Disorders (1622) · Leukemia, Lymphoid (1492)
Cyclophosphamide (383) · Dexamethasone (331) · Cytarabine (306) · fludarabine (296) · Azacitidine (236) · venetoclax (223) · Lenalidomide (211) · fludarabine phosphate (202) · Bortezomib (175) · Rituximab (163) · Filgrastim (139) · Calcium Dobesilate (128) · Decitabine (124) · Melphalan (122) · Granulocyte Colony-Stimulating Factor (92)
National Cancer Institute (NCI) (266) · M.D. Anderson Cancer Center (221) · City of Hope Medical Center (80) · Fred Hutchinson Cancer Center (78) · Novartis Pharmaceuticals (74) · Memorial Sloan Kettering Cancer Center (68) · Celgene (62) · GlaxoSmithKline (58) · Mayo Clinic (56) · Washington University School of Medicine (53) · Dana-Farber Cancer Institute (52) · AbbVie (51) · Institute of Hematology & Blood Diseases Hospital, China (49) · Janssen Research & Development, LLC (44) · National Heart, Lung, and Blood Institute (NHLBI) (44)
United States (3538) · China (693) · France (384) · Spain (352) · Germany (341) · United Kingdom (315) · Australia (307) · Canada (307) · Italy (277) · Japan (170) · South Korea (154) · Netherlands (143) · Israel (116) · Belgium (105) · Poland (101)
Jorge Cortes, MD (13)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 32499241, PMID 42013378, PMID 28054442, PMID 36100310, PMID 36240296, PMID 37022569, PMID 41429239, PMID 42133908, PMID 24615776, PMID 24615777, PMID 25495795, PMID 26943915, PMID 27400247, PMID 28803351, PMID 31355467, PMID 33883258, PMID 34687939, PMID 34889384, PMID 35075289, PMID 35622074, PMID 35829925, PMID 37192741, PMID 37486616, PMID 38507688, PMID 39368878, PMID 40195173, PMID 16775234, PMID 17880439, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 22149959, PMID 22510871, PMID 23400739, PMID 23660685, PMID 23886836, PMID 24055823, PMID 24615778, PMID 24782509, PMID 24916507, PMID 25310303, PMID 25317870, PMID 25319501, PMID 25381051
2023 (80), P30CA033572 (46), 2018 (38), 2019 (37), 2014 (36), 2015 (36), 2016 (33), P30CA015704 (30), 2025 (28), 2017 (26), P30CA016672 (25), U01CA076576 (25), P30CA015083 (24), P30CA006973 (22), U01CA070095 (19)